Hydroxychloroquine Global Market Opportunities and Strategies to 2035

This report describes and explains the hydroxychloroquine market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global hydroxychloroquine market reached a value of nearly $873.4 million in 2025, having grown at a compound annual growth rate (CAGR) of 7% since 2020. The market is expected to grow from $873.4 million in 2025 to $1.17 billion in 2030 at a rate of 6.2%. The market is then expected to grow at a CAGR of 4.6% from 2030 and reach $1.47 billion in 2035.

Growth in the historic period resulted from persistent malaria burden in endemic regions, rising public health programs and government procurement of antimalarial drugs, growing incidence of autoimmune disorders and increasing awareness and early diagnosis of autoimmune disorders. Factors that negatively affected growth in the historic period were supply shortages and distribution disruptions and rising concerns regarding retinal toxicity and side effects.

Going forward, rising healthcare expenditure, rising investment in infectious disease control programs, growing chronic care management programs for autoimmune patients and expanding government-supported access to antirheumatic medications will drive the growth. Factors that could hinder the growth of the hydroxychloroquine market in the future include growing adoption of biologic and targeted therapies, shift toward artemisinin-based combination therapies (ACTs) reducing reliance and impact of trade war and tariff.

Market trends for the hydroxychloroquine market include emergence of precision-targeted combination treatments and enhanced hydroxychloroquine production capabilities support global healthcare demand.

The hydroxychloroquine market is segmented by drug activity into anti-malarial drug, anti-rheumatic drug, lupus suppressant drug, anti COVID-19 drug and other drug activity. The anti-malarial drug market was the largest segment of the hydroxychloroquine market segmented by drug activity, accounting for 45.2% or $394.4 million of the total in 2025. Going forward, the lupus suppressant drug segment is expected to be the fastest-growing segment in the hydroxychloroquine market segmented by drug activity, at a CAGR of 7.4% during 2025-2030.

The hydroxychloroquine market is segmented by formulation into tablets and injection. The tablets was the largest segment of the hydroxychloroquine injection segmented by formulation, accounting for 82.7% or $722 million of the total in 2025. Going forward, the injection segment is expected to be the fastest-growing segment in the hydroxychloroquine market segmented by formulation, at a CAGR of 6.5% during 2025-2030.

The hydroxychloroquine market is segmented by distribution channel into hospital pharmacy, online pharmacy, specialty drug stores and retail pharmacy. The hospital pharmacy market was the largest segment of the hydroxychloroquine market segmented by distribution channel, accounting for 45.8% or $399.9 million of the total in 2025. Going forward, the online pharmacy segment is expected to be the fastest-growing segment in the hydroxychloroquine market segmented by distribution channel, at a CAGR of 9.1% during 2025-2030.

Asia Pacific was the largest region in the hydroxychloroquine market, accounting for 28.2% or $246 million of the total in 2025. It was followed by Africa, North America and then the other regions. Going forward, the fastest-growing regions in the hydroxychloroquine market will be Asia Pacific and Western Europe where growth will be at CAGRs of 7.3% and 6.3% respectively. These will be followed by North America and Eastern Europe where the markets are expected to grow at CAGRs of 6.2% and 5.9% respectively.

The global hydroxychloroquine market is fairly fragmented, with a large number of small players operating in the market. The top 10 competitors in the market made up 23.88% of the total market in 2024. Sun Pharmaceutical Industries Ltd. was the largest competitor with a 3.42% share of the market, followed by Sanofi SA with 2.72%, Teva Pharmaceutical Industries with 2.64%, Zydus Lifesciences Limited (formerly Cadila Healthcare Limited), with 2.48%, Ipca Laboratories Ltd., with 2.44%, Viatris SA, with 2.21%, Sandoz International GmbH with 2.20%, Dr. Reddy’s Laboratories Ltd. with 1.99%, Lupin Limited with 1.96% and Aurobindo Pharma USA Inc. with 1.82%.

The top opportunities in the hydroxychloroquine market segmented by drug activity will arise in the anti-malarial drug segment, which will gain $120.7 million of global annual sales by 2030. The top opportunities in the hydroxychloroquine market segmented by formulation will arise in the tablets segment, which will gain $249.2 million of global annual sales by 2030.The top opportunities in the hydroxychloroquine market segmented by distribution channel will arise in the hospital pharmacy segment, which will gain $139.4 million of global annual sales by 2030. The hydroxychloroquine market size will gain the most in the USA at $67 million.

Player-adopted strategies in the hydroxychloroquine market include focus on enhancing business operations through strategic acquisitions, strategic partnerships, biosimilars expansion, generic drug launches and manufacturing capacity expansion.

Market-trend-based strategies for the hydroxychloroquine market include focus on increasingly focusing on the development and advancement of innovative therapeutic applications, combination treatment strategies and precision-targeted clinical research programs that leverage hydroxychloroquine’s immunomodulatory and introduction of authorized generic formulations, advanced manufacturing capabilities and expanded regulatory approvals to enhance treatment accessibility, supply reliability and cost-effective therapeutic availability.

To take advantage of the opportunities, the analyst recommends the hydroxychloroquine companies to focus on precision oncology partnerships and combination therapy development, focus on authorized generic expansion and supply chain reliability, focus on lupus suppressant drug applications and autoimmune treatment demand, focus on injection formulations and hospital-based treatment demand, expand in emerging markets, continue to focus on developed markets, focus on expanding regional distribution networks and digital supply access, focus on tiered and value-based pricing models, focus on evidence-based medical communication, focus on patient awareness and digital outreach, focus on online pharmacy expansion and digital prescription access.

This product will be delivered within 3-5 business days.